ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19,934 ARS | +2.53% |
|
+8.92% | +96.73% |
| 01:00pm | US FDA advisers to review Eli Lilly Alzheimer's drug | RE |
| 12:55pm | Eli Lilly Study Shows Tirzepatide Superior to Placebo | MT |
| Sales 2024 * | 42.98B 38,639B | Sales 2025 * | 52.62B 47,309B | Capitalization | 765B 688,037B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 10,727B | Net income 2025 * | 16.55B 14,881B | EV / Sales 2024 * | 18.2 x |
| Net Debt 2024 * | 18.07B 16,245B | Net Debt 2025 * | 15B 13,483B | EV / Sales 2025 * | 14.8 x |
| P/E ratio 2024 * |
63.6
x | P/E ratio 2025 * |
45.8
x | Employees | 43,000 |
| Yield 2024 * |
0.61% | Yield 2025 * |
0.71% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +2.53% | ||
| 1 week | +8.92% | ||
| Current month | +8.92% | ||
| 1 month | +32.94% | ||
| 3 months | +39.88% | ||
| 6 months | +90.62% | ||
| Current year | +96.73% |
1 week
19 064.50
20 631.00
1 month
14 429.0020 631.00
Current year
9 938.3620 631.00
1 year
3 879.2120 631.00
3 years
648.5720 631.00
5 years
328.5720 631.00
10 years
14.4320 631.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 19,934 | +2.53% | 4,023 |
| 24-06-06 | 19,442 | -0.19% | 2,815 |
| 24-06-05 | 19,479 | -0.29% | 2,614 |
| 24-06-04 | 19,536 | +1.62% | 4,409 |
| 24-06-03 | 19,226 | +5.05% | 4,346 |
End-of-day quote Buenos Aires S.E., June 06, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.94% | 248B | |
| -1.51% | 219B | |
| +11.31% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B | |
| +0.10% | 123B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
